全文获取类型
收费全文 | 600篇 |
免费 | 33篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 39篇 |
口腔科学 | 1篇 |
临床医学 | 19篇 |
内科学 | 133篇 |
皮肤病学 | 83篇 |
神经病学 | 11篇 |
特种医学 | 23篇 |
外科学 | 67篇 |
综合类 | 13篇 |
预防医学 | 7篇 |
眼科学 | 6篇 |
药学 | 12篇 |
肿瘤学 | 213篇 |
出版年
2023年 | 8篇 |
2022年 | 6篇 |
2021年 | 17篇 |
2020年 | 8篇 |
2019年 | 17篇 |
2018年 | 27篇 |
2017年 | 17篇 |
2016年 | 21篇 |
2015年 | 17篇 |
2014年 | 17篇 |
2013年 | 18篇 |
2012年 | 56篇 |
2011年 | 52篇 |
2010年 | 39篇 |
2009年 | 18篇 |
2008年 | 34篇 |
2007年 | 36篇 |
2006年 | 40篇 |
2005年 | 34篇 |
2004年 | 27篇 |
2003年 | 18篇 |
2002年 | 36篇 |
2001年 | 5篇 |
2000年 | 11篇 |
1999年 | 5篇 |
1998年 | 4篇 |
1997年 | 5篇 |
1996年 | 8篇 |
1995年 | 4篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 4篇 |
1988年 | 1篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1984年 | 3篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1975年 | 1篇 |
1947年 | 1篇 |
排序方式: 共有635条查询结果,搜索用时 15 毫秒
81.
Amoh Y Bouvet M Li L Tsuji K Moossa AR Katsuoka K Hoffman RM 《Clinical & experimental metastasis》2006,23(7-8):315-322
Nestin regulatory-element-driven green fluorescent protein (ND-GFP) transgenic mice highly express GFP in proliferating endothelial
cells and nascent blood vessels. In the present study, we visualized angiogenesis in experimental lung and liver metastases
by GFP imaging in the ND-GFP transgenic mice. The murine melanoma cell line, B16F10 expressing red fluorescent protein (RFP),
was injected i.v. in ND-GFP mice. ND-GFP was highly expressed in proliferating nascent blood vessels in the tumors that developed
in the lung after tail vein injection, and in the tumors that developed in the liver after portal vein injection of RFP-expressing
melanoma cells. Liver metastasis and angiogenesis were imaged intravitally. Doxorubicin significantly decreased metastatic
angiogenesis in the liver. These results demonstrate a new imageable model of angiogenesis in metastasis in the liver and
the lung. This new model should enable further understanding of the onset of angiogenesis in metastasis and its effect on
metastatic growth. The model will serve as a unique screen for inhibitors of angiogenesis of metastatic tumors. The fact that
liver-metastasis angiogenesis can be imaged in the live animal enables real-time studies of the effect of angiogenesis inhibitors. 相似文献
82.
K Maebayashi N Mitsuhashi T Takahashi H Sakurai H Niibe 《International journal of radiation oncology, biology, physics》1999,44(3):677-682
PURPOSE: We reported that two established rat yolk sac tumor cell lines differ in their radiosensitivity by 1.7 fold, and the variation is most likely manifested by the differences seen in their apoptotic response. We investigated the relationship between radiosensitivity and p53 in these cell lines. METHODS AND MATERIALS: We assessed the status of p53 in cell lines by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and sequence analysis, and also analyzed protein expression of p53, p21, and bax as a function of time after irradiation to determine the signal transduction for p53 by immunoblotting. RESULTS: A band shift was observed only in exon 7 for the radioresistant NMT-1R cells and no band shift was detected for the radiosensitive NMT-1 cells. A band shift was confirmed also at the mRNA level. Exon 7 of p53 DNA showed a three base substitution of DNA at codon 267 to 268. Expression of p53, p21, and bax proteins in NMT-1R cells did not change after 10 Gy irradiation; however, in NMT-1 cells, the expression of these proteins was increased from 1-12 h after irradiation. CONCLUSION: A loss of p53 function by radiation-induced mutation of p53 decreased the radiosensitivity in these cell lines. 相似文献
83.
Satoshi Yamasaki Akiko Miyagi-Maeshima Yasuo Kakugawa Yoshihiro Matsuno Fusako Ohara-Waki Shigeo Fuji Yuriko Morita-Hoshi Masakazu Mori Sung-Won Kim Shin-ichiro Mori Takahiro Fukuda Ryuji Tanosaki Tadakazu Shimoda Kensei Tobinai Daizo Saito Yoichi Takaue Takanori Teshima Yuji Heike 《International journal of hematology》2013,97(3):421-426
Colonoscopic evaluation of mucosal tissues after allogeneic hematopoietic stem cell transplantation (HSCT) is very useful in evaluating pathogenesis and diagnosis of intestinal graft-versus-host disease (GVHD). However, information on the timing and sites of biopsies and the immunohistological evaluation of mucosal tissues for diagnosing intestinal GVHD, especially following reduced-intensity (RIC) regimens, remains very limited. A total of 33 patients with histologically proven GVHD after allogeneic HSCT with RIC (n = 23) and myeloablative conditioning (MAC, n = 10) regimens were enrolled in the present study. Colonoscopy was performed due to gastrointestinal symptoms, especially diarrhea and anorexia. Sites of biopsies with the worst histopathological grading were the terminal ileum in 67 % of patients. In the RIC group, the onset of diarrhea prior to colonoscopy examination was later (median: RIC, 57 vs. MAC, 27 days) and the number of patients who developed abdominal pain tended to be higher (RIC, 70 % vs. MAC, 30 %). A lower number of CD4+ cells and a higher ratio of Foxp3+ cells to CD4+ cells were detected in the involved lesions of intestinal GVHD following RIC. These differences in the RIC and MAC groups suggest that regimen-specific therapeutic strategies are required for diagnosing intestinal GVHD. 相似文献
84.
Minimally invasive uncemented total hip arthroplasty through an anterolateral approach with a shorter skin incision 总被引:10,自引:0,他引:10
Fujio Higuchi Masafumi Gotoh Noboru Yamaguchi Ritsu Suzuki Yoshifumi Kunou Kazuo Ooishi Kensei Nagata 《Journal of orthopaedic science》2003,8(6):812-817
Total hip arthroplasty using a short skin incision has been associated with great controversy. It has still not yet been demonstrated that a shorter skin incision is efficient or safe for patients. Here, we review 212 cases of uncemented total hip arthroplasty performed since 1999 using the anterolateral approach and a shorter skin incision. Patients were divided into three groups according to the length of the incision at the end of surgery; incisions of 10cm or less were defined as mini (n = 115) and incisions of 10–15cm as short (n = 70); these two groups were defined as shorter skin incision groups. Incisions longer than 15cm in patients undergoing the standard procedure were defined as conventional and served as the controls (n = 27). Statistically significant differences were found with regard to operative duration and intraoperative blood loss: the shorter the length of the incision, the shorter the operative duration and the smaller the intraoperative blood loss. There was no significant difference in postoperative bleeding or in the incidence of complications among the three groups. Total blood losses in the shorter groups were each statistically significant less than that in the conventional group. Comparing the mini group to the short group, the length of the skin incision was influenced by the body mass index (BMI) and gender. For those with a high BMI and for male patients, a slightly longer incision was necessary. We concluded that total hip arthroplasty through a mini or short incision was indeed efficient for patients compared with total hip arthroplasty using a conventional incision. 相似文献
85.
Daisuke Takahari Narikazu Boku Junki Mizusawa Atsuo Takashima Yasuhide Yamada Takayuki Yoshino Kentaro Yamazaki Wasaburo Koizumi Kazutoshi Fukase Kensei Yamaguchi Masahiro Goto Tomohiro Nishina Takao Tamura Akihito Tsuji Atsushi Ohtsu 《The oncologist》2014,19(4):358-366
Background.
In advanced gastric cancer (AGC), no globally accepted prognostic scoring system has been developed. Therefore, we explored baseline prognostic factors in Japanese AGC patients using the data from a randomized controlled trial, Japan Clinical Oncology Group (JCOG) 9912, which investigated the efficacy of systemic chemotherapy as a first-line treatment.Patients and Methods.
Prognostic factors and prognostic indices for overall survival were screened and evaluated in patients enrolled in JCOG9912 using the Cox proportional hazard model. The Royal Marsden Hospital prognostic model was also applied to the JCOG9912 trial.Results.
A total of 650 (92.3%) of the 704 patients randomized in the JCOG9912 trial, for whom complete data were available for multivariate analyses, was included in the present study (5-fluorouracil arm, n = 215; irinotecan plus cisplatin arm, n = 216; S-1 arm, n = 219). The median survival time (MST) for all patients was 11.8 months. To construct a prognostic index, we selected four risk factors by multivariate analysis: performance status ≥ 1, number of metastatic sites ≥ 2, no prior gastrectomy, and elevated alkaline phosphatase. MSTs were 17.0 months for patients categorized into the low-risk group, who had zero or one risk factor (n = 225); 10.4 months for patients in the moderate-risk group, who had two or three risk factors (n = 368); and 5.0 months for patients in the high-risk group, who had all four risk factors (n = 57).Conclusion.
In the present study, we propose a new prognostic index for patients with AGC. This can be used for more appropriate patient stratification in future clinical trials. 相似文献86.
Seki-Nakamura K Maebayashi K Nasu-Izumi S Akimoto T Mitsuhashi N 《Journal of radiation research》2011,52(3):351-359
We conducted a prospective study to assess the anxiety and salivary Chromogranin A (CgA), which is considered to be a biomarker of the stress response, in outpatients receiving breast conserving surgery followed by radiation therapy (RT) to the whole breast. Fifty consecutive patients who received whole-breast RT were enrolled in this study. The anxiety levels were measured by the State-Trait Anxiety Inventory (STAI) at the beginning of RT (baseline), 30 Gy, completion of RT, and 1 and 3 months after RT. Salivary CgA levels were also measured at the same time. The mean state anxiety score for all patients was 46.16 with a standard error (SE) of 1.57 at the beginning of RT (baseline) which continued to decline during and after RT. It reached its lowest score with 36.34 ± 1.56 at 3 months after RT (p < 0.0001). The mean trait anxiety score for all patients was 43.10 ± 1.54 at baseline and remained constant during RT but began to decline after completion of RT and reached a low level at 3 months after RT (p = 0.0021). The mean salivary CgA concentration for all patients demonstrated no consistent trends over time, but at 30 Gy the concentration showed a significant decreasing pattern (p = 0.0473). Salivary CgA concentrations and state anxiety and trait anxiety scores at all time points showed no correlation. The mean anxiety scores measured by STAI showed no positive correlation with salivary CgA concentration for breast cancer patients undergoing radiation therapy following breast conserving surgery. 相似文献
87.
88.
Chronic kidney disease (CKD) is a public health concern that affects approximately 10% of the global population. CKD is associated with poor outcomes due to high frequencies of comorbidities such as heart failure and cardiovascular disease. Uremic toxins are compounds that are usually filtered and excreted by the kidneys. With the decline of renal function, uremic toxins are accumulated in the systemic circulation and tissues, which hastens the progression of CKD and concomitant comorbidities. Gut microbial dysbiosis, defined as an imbalance of the gut microbial community, is one of the comorbidities of CKD. Meanwhile, gut dysbiosis plays a pathological role in accelerating CKD progression through the production of further uremic toxins in the gastrointestinal tracts. Therefore, the gut-kidney axis has been attracting attention in recent years as a potential therapeutic target for stopping CKD. Trimethylamine N-oxide (TMAO) generated by gut microbiota is linked to the progression of cardiovascular disease and CKD. Also, advanced glycation endproducts (AGEs) not only promote CKD but also cause gut dysbiosis with disruption of the intestinal barrier. This review summarizes the underlying mechanism for how gut microbial dysbiosis promotes kidney injury and highlights the wide-ranging interventions to counter dysbiosis for CKD patients from the view of uremic toxins such as TMAO and AGEs. 相似文献
89.
Satoshi Murahashi Daisuke Takahari Takeru Wakatsuki Naoki Fukuda Takashi Ichimura Mariko Ogura Masato Ozaka Eiji Shinozaki Izuma Nakayama Tomohiro Matsushima Hiroki Osumi Keisho Chin Kensei Yamaguchi 《International journal of clinical oncology / Japan Society of Clinical Oncology》2018,23(1):92-97
Background
The REGARD trial demonstrated that ramucirumab monotherapy improved both overall survival (OS) and progression-free survival (PFS) compared with best supportive care plus placebo as second-line treatment for patients with advanced gastric cancer. However, the efficacy and safety of ramucirumab monotherapy for previously treated Japanese patients with advanced gastric cancer remains unknown.Methods
Previously treated Japanese patients with advanced gastric cancer who received ramucirumab monotherapy between June 2015 and March 2016 at the Cancer Institute Hospital were enrolled in the study. OS, PFS, best overall response, and safety profiles were retrospectively evaluated.Results
Nineteen patients were enrolled in this study. Ramucirumab monotherapy was generally administered as third-line therapy. After a median follow-up period of 7.4 months, the median PFS was 2.1 months (95% CI 1.0–3.5), and median OS was 12.9 months (95% CI 2.3, not reached). In 13 patients who had measurable lesions on radiologic examination, partial response was observed in one patient (7.7%) and stable disease was observed in five patients (38.5%). A total of 12 patients (63.2%) had adverse events (AEs). Common AEs included hypertension (8 patients, 42.1%), fatigue (6 patients, 31.6%), and bleeding (5 patients, 26.3%). Grade 3 AEs included gastrointestinal bleeding and aspiration pneumonia (1 patient each, 5.3%).Conclusions
Our data suggest that ramucirumab monotherapy in Japanese patients with previously treated advanced gastric cancer has comparable efficacy and safety profiles as reported in the REGARD trial.90.
Hiroki Hara Shigenori Kadowaki Masako Asayama Akira Ooki Toko Yamada Takako Yoshii Kensei Yamaguchi 《International journal of clinical oncology / Japan Society of Clinical Oncology》2018,23(2):275-280